Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients.
about
Disruption of platelet-derived growth factor-dependent phosphatidylinositol 3-kinase and phospholipase Cγ 1 activity abolishes vascular smooth muscle cell proliferation and migration and attenuates neointima formation in vivoPharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid LeukemiaGenetics of myeloproliferative neoplasmsImatinib in chronic myeloid leukemia: an overviewResistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment optionsTransport mechanisms and their pathology-induced regulation govern tyrosine kinase inhibitor delivery in rheumatoid arthritisImpact of long-term exposure to the tyrosine kinase inhibitor imatinib on the skeleton of growing ratsInhibition of an Erythrocyte Tyrosine Kinase with Imatinib Prevents Plasmodium falciparum Egress and Terminates ParasitemiaImatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction.The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitorsA study to explore the correlation of ABCB1, ABCG2, OCT1 genetic polymorphisms and trough level concentration with imatinib mesylate-induced thrombocytopenia in chronic myeloid leukemia patients.Imatinib plasma trough concentration and its correlation with characteristics and response in Chinese CML patients.Common drugs inhibit human organic cation transporter 1 (OCT1)-mediated neurotransmitter uptake.Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia.Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia.The pharmacogenetics of imanitib.Effects of imatinib mesylate on the pharmacokinetics of paracetamol (acetaminophen) in Korean patients with chronic myelogenous leukaemia.Mechanisms of resistance to imatinib mesylate in KIT-positive metastatic uveal melanoma.Selecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutationsSmall molecule ErbB inhibitors decrease proliferative signaling and promote apoptosis in philadelphia chromosome-positive acute lymphoblastic leukemia.Fluid retention associated with imatinib treatment in patients with gastrointestinal stromal tumor: quantitative radiologic assessment and implications for managementWill imatinib compromise reproductive capacity?Imatinib mesylate: past successes and future challenges in the treatment of gastrointestinal stromal tumors.Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets.Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium reportIn vitro blood distribution and plasma protein binding of the tyrosine kinase inhibitor imatinib and its active metabolite, CGP74588, in rat, mouse, dog, monkey, healthy humans and patients with acute lymphatic leukaemia.Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study.Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein.A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies.Targeting Filarial Abl-like Kinases: Orally Available, Food and Drug Administration-Approved Tyrosine Kinase Inhibitors Are Microfilaricidal and Macrofilaricidal.Targeted therapies in the treatment of colorectal cancers.Monitoring imatinib plasma concentrations in chronic myeloid leukemiaPhase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancerHuman hepatocyte assessment of imatinib drug-drug interactions - complexities in clinical translation.Imatinib increases oxygen delivery in extracellular matrix-rich but not in matrix-poor experimental carcinoma.Recent advances in targeted therapy of human myelogenous leukaemia.Suicide attempt with an overdose of imatinib.Simultaneous quantification of imatinib and its main metabolite N-demethyl-imatinib in human plasma by liquid chromatography-tandem mass spectrometry and its application to therapeutic drug monitoring in patients with gastrointestinal stromal tumor.Comparative pharmacokinetic evaluation and bioequivalence study of three different formulations of Imatinib Mesylate in CML patientsDelayed Imatinib Treatment for Acute Spinal Cord Injury: Functional Recovery and Serum Biomarkers
P2860
Q24306656-3EF4C027-902D-4DB0-A985-DE443099F473Q26781539-084CBEE3-E2D0-417C-A5B4-CCAC80348C0BQ26823651-FE59A43F-8BE6-43D6-8E9B-1F17CACE85FFQ26865086-6666A1F5-BA03-40B9-871C-FE5C1B427BBAQ27028181-33A4C6CA-BC8A-496C-9A57-262592A15230Q28484465-6B5C4EC6-641B-4E32-975C-CCEF3769F1BBQ28548625-E0803C31-1158-4B37-AFC2-74E5EAC4002EQ28552868-765F2B8E-AEA2-4691-BD85-5D97C3B6BD44Q33390293-64404AE9-B71B-4EBC-9EEE-A2E12BF855BEQ33418324-756D1AC6-9E35-4450-8ED2-4494C487EA09Q33427392-BF26F53E-668D-441B-8F71-6AF5DD9136BBQ33557847-46BB6AF5-9C16-46B5-A461-1624E77A8DA4Q33584577-A6EC788D-B2E9-4139-A2E6-6E154B429A23Q33926222-1FB6CA38-95B7-46B0-A146-F23BE3C4A5C6Q34016866-1DD44812-8506-4F8A-BE9D-BD3CF76C4E6DQ34469295-4D3E9D8A-3F94-4010-8E80-557CB3884B6AQ34580581-38EF7B09-5938-40C9-A4A3-4FC3CAE488D2Q34660509-9650C07C-2567-43F0-8160-50F02215E1E9Q34804754-DF916709-62D5-4123-8381-6014FD1048E3Q34926036-0888B43F-1F61-445E-82A9-FC5BD51E29FCQ35140171-A1DF396B-78DF-4FD3-A60D-B08A5798B62CQ35584349-BA3BB5FD-0A75-4539-8130-39381F88CB23Q35607790-C89EBB13-D486-4C36-B643-47CD9E689740Q35629006-7BB9D45B-43FD-4C09-8202-8DC727D449D4Q35799962-A6EC5F46-2B50-49BB-9FC1-B5159CC6DDF4Q35826342-02F844B8-448F-4E45-9BE0-95A2DE74FC09Q35827125-F7D7F71C-8B53-4547-A5E5-AE099BE4680FQ35827616-F006C627-E65E-42C7-BF03-88AD1B82845CQ35865095-24539776-80EE-4688-9A67-A1B366D2E861Q35965183-CD7662C6-BEAC-44C4-B4E7-06A25AEDD2CAQ36108618-64824751-6CA1-49AF-93E6-82868051FC6CQ36153597-B9532917-3D3A-4D0F-9F1F-9BB5FFEB93E7Q36166836-5719FB25-7250-41B8-906E-BB39D68FFE0EQ36243653-6899B3B7-540A-449B-888C-DA8EED32C122Q36288883-E5B7D5F6-2F21-4385-A035-21ECDD3E8950Q36318531-A3B40985-0FA8-4F69-9B0B-46088556A504Q36390299-97B67AFC-150E-497D-9CC3-6AABB4366658Q36407123-98491B94-478F-4E42-B586-E3A735CCAE87Q36566250-8380B760-CE56-454E-9241-8D0D34202E2BQ36576063-502EBCE3-CBCA-4435-9E4D-5F2CE8E2388B
P2860
Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Pharmacokinetics and pharmacod ...... nic myeloid leukemia patients.
@en
Pharmacokinetics and pharmacod ...... nic myeloid leukemia patients.
@nl
type
label
Pharmacokinetics and pharmacod ...... nic myeloid leukemia patients.
@en
Pharmacokinetics and pharmacod ...... nic myeloid leukemia patients.
@nl
prefLabel
Pharmacokinetics and pharmacod ...... nic myeloid leukemia patients.
@en
Pharmacokinetics and pharmacod ...... nic myeloid leukemia patients.
@nl
P2093
P921
P356
P1476
Pharmacokinetics and pharmacod ...... nic myeloid leukemia patients.
@en
P2093
Amy Racine-Poon
Charles L Sawyers
Debra Resta
Marianne Rosamilia
Michael Hayes
Moshe Talpaz
Peter Lloyd
Renaud Capdeville
P304
P356
10.1200/JCO.2004.03.050
P407
P577
2004-03-01T00:00:00Z